(1 - 18 von 22
)
Penn's James Wilson takes new role at gene therapy ...
www.bizjournals.com
— Olivier Danos, previously senior vice president for cell and gene therapy at Biogen, to serve as chief scientific officer. The hiring is a ... › news
Biogen enters eye-treatment arena with AGTC deal | Reuters
www.reuters.com
Biogen said on Thursday it had forged a deal with AGTC to develop gene-based therapies for a range of eye diseases, marking the company's entry into...
TxCell Appoints Biogen's Dr. Olivier Danos, Pioneer in Gene Therapy...
www.finanznachrichten.de
SAB now composed of four world-leading immunology experts, including Prof. Zelig Eshhar, who recently received the Novartis Prize for Clinical Immunology...
People in the News: Olivier Danos, Frank Witney, John Radak |...
www.genomeweb.com
Biogen Idec has hired Olivier Danos as senior VP of gene therapy. Danos will report to Douglas Williams, executive VP of R&D at Biogen Idec. At Biogen Idec, he...
www.wallstreet-online.de
www.wallstreet-online.de
Olivier Danos, PhD aus der Diskussion: LYS.PA (Mkap €22 M) (Cash €33 M) Orphan Disease P3 partner Sarepta (SRPT) Autor (Datum des Eintrages): Biohero (
The Alliance for Regenerative Medicine Releases Agenda for Fifth...
www.firmenpresse.de
Olivier Danos, Ph.D., Chief Scientific Officer, REGENXBIO (moderator) James M. Wilson, M.D., Ph.D., Rose H. Weiss Professor and Director, Orphan Disease Center; Professor of Medicine and Pediatrics; Director, Gene Therapy Program, Perelman School of Medicine, University of Pennsylvania Panel I: Cell Therapy Beyond Oncology: Where Does the Greatest Potential Lie? …
TxCell: Financial Information for the 3rd Quarter of 2016
www.finanznachrichten.de
In August 2016, TxCell appointed Olivier Danos, PhD, ...
TxCell appoints Biogen's Dr Olivier Danos to its Scientific Advisory ...manufacturingchemist.com › news › article_page
manufacturingchemist.com
· 'Dr Olivier Danos has pioneered technologies of central importance in the field of gene therapy and genome editing,' said Arnaud Foussat, ...
REGENX Biosciences and LYSOGENE Enter Into Exclusive License...
www.finanznachrichten.de
... therapy may become an outstanding treatment option," said Olivier Danos PhD , Co-founder and Senior Scientific Advisor to LYSOGENE.
Gene Therapy Takes Center Stage at NORD Summit
adrenoleukodystrophynews.com
— The panel included Olivier Danos, PhD, senior vice president and chief scientific officer at Regenxbio; Neil Horikoshi, CEO and executive ... › ...
Regenxbio Receives FDA Orphan Drug Designation For Potential Duchenne...
www.contractpharma.com
Marks a milestone in the development of RGX-202 and highlights the need for potential new treatment options for patients with Duchenne.
Biogen Appoints Gene Therapy SVP - Contract Pharma
www.contractpharma.com
— Olivier Danos, Ph.D., has been named senior vice president of Gene Therapy at Biogen Idec. Dr. Danos reports to Douglas Williams, Ph.D., ... › ...
Phase 1/2 Trial Set to Test RGX-202, Gene Therapy for ...
musculardystrophynews.com
— “We are excited to advance RGX-202, our investigational gene therapy for patients with Duchenne, into the clinic,” Olivier Danos, PhD, ... › ...
REGENXBIO Enhances and Expands Scientific Leadership
www.globenewswire.com
— Appoints Gene Therapy Industry Leader Olivier Danos, Ph.D., as Chief Scientific Officer... › ...
REGENXBIO to Develop New Therapies for HAE, Other ...
angioedemanews.com
— ... of research and development of AAV-mediated antibody gene therapies,” said Olivier Danos, PhD, chief scientific officer of Regenxbio. › news
sortiert nach Relevanz / Datum